Abstract: The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
Type:
Grant
Filed:
October 17, 2018
Date of Patent:
June 1, 2021
Assignee:
FERRING B.V.
Inventors:
Bjarke Mirner Klein, Jens Peter Norgaard
Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
Type:
Grant
Filed:
December 7, 2018
Date of Patent:
June 1, 2021
Assignee:
Abbott Laboratories
Inventors:
Beth McQuiston, Saul A. Datwyler, Raj Chandran
Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). Also disclosed here are methods that aid in determining whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels and changes in levels of UCH-L1 in one or more samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
Abstract: Biomarkers and methods for screening expression levels of the biomarkers for predicting suicidality (referred herein to suicidal ideation and actions, future hospitalizations and suicide completion) are disclosed. Also disclosed are quantitative questionnaires and mobile applications for assessing affective state and for assessing socio-demographic and psychological suicide risk factors, and their use to compute scores that can predict suicidality. Finally, an algorithm that combines biomarkers and computer apps for identifying subjects who are at risk for committing suicide is disclosed, as well as methods to mitigate and prevent suicidality based on the biomarkers and computer apps.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
April 27, 2021
Assignee:
Indiana University Research and Technology Corporation
Abstract: The present application provides an inhibitory compound, such as a peptide, and methods for using the inhibitory compound in the treatment, diagnosis or monitoring of cognitive and mood disorders that are typically associated with memory loss and/or loss of executive function. In one example, the inhibitory compound is a peptide that mimics the N-terminal sequence of the intracellular loop of ?5 subunit of ?5GABAA receptors. Also provided are compositions and methods for treating a disorder associated with memory loss or loss of executive function. The therapeutic method comprises the step of inhibiting binding of radixin to ?5GABAA receptors, for example, by administration of the presently described inhibitory compound or peptide.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
April 20, 2021
Assignees:
The Governing Council of the University of Toronto, Banting Institute
Abstract: The present invention provides for the first time the identification of fetal neural exosomal biomarkers isolated from maternal plasma useful in diagnosing fetal neurodevelopmental outcomes. The invention also provides the identification of neonatal neural exosomal biomarkers isolated from neonatal plasma useful in diagnosing neonatal neurodevelopmental outcomes The present invention therefore provides methods, kits and systems for diagnosing fetal neurodevelopmental outcomes, by examining relevant proteins and RNA in fetal neural exosomes isolated from a maternal plasma and neonatal neural exosomes isolated from neonatal plasma.
Type:
Grant
Filed:
January 6, 2017
Date of Patent:
March 30, 2021
Assignee:
TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.
Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
Type:
Grant
Filed:
October 17, 2016
Date of Patent:
January 26, 2021
Assignees:
Georgetown University, University of Rochester
Inventors:
Howard J. Federoff, Massimo S. Fiandaca, Amrita K. Cheema, Mark E. Mapstone, Xiaogang Zhong
Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
Type:
Grant
Filed:
May 18, 2016
Date of Patent:
January 26, 2021
Assignees:
Georgetown University, University of Rochester
Inventors:
Howard J. Federoff, Massimo S. Fiandaca, Amrita K. Cheema, Mark E. Mapstone
Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
Type:
Grant
Filed:
May 27, 2015
Date of Patent:
January 12, 2021
Assignees:
Georgetown University, University of Rochester
Inventors:
Massimo S. Fiandaca, Mark E. Mapstone, Howard J. Federoff, Xiaogang Zhong, Amrita K. Cheema
Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1.
Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.
Type:
Grant
Filed:
January 29, 2018
Date of Patent:
December 29, 2020
Assignee:
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Inventors:
Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1.
Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).
Type:
Grant
Filed:
June 2, 2017
Date of Patent:
November 24, 2020
Assignees:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, LEVO THERAPEUTICS, INC.
Inventors:
Lisa Cole Burnett, Dieter Egli, Rudolph L. Leibel, Sara Cotter
Abstract: The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorders. The present invention also provides methods for predicting a likelihood of ASD. In one embodiment, a method for treating a female patient having a high risk factor of having children with ASD comprises the steps of (a) identifying in a sample taken from the female patient the presence of AT-1 antibodies; and (b) administering an effective amount of an AT-1 inhibitor or inhibitor of AT-1 antibodies to the female patient.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
November 17, 2020
Assignee:
The Johns Hopkins University
Inventors:
Avindra Nath, Tongguang Wang, Christina Michelle Morris-Berry, Harvey Singer
Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
Type:
Grant
Filed:
July 10, 2017
Date of Patent:
October 20, 2020
Assignees:
UNIVERSITY OF SOUTH FLORIDA, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Inventors:
Huntington Potter, Timothy Boyd, Heather Sevey Lawrence Jim
Abstract: The invention provides biomarkers and methods for determining the risk of a subject for developing mild traumatic brain injuries (mTBI). In some aspects, the methods of the invention also determine the fitness of a subject for participating in an activity with increased chances of receiving a head impact. Some embodiments of the invention are directed to kits for determining the risk of a subject for developing mTBI or the fitness of a subject for participating in an activity with increased chances of receiving a head impact.
Type:
Grant
Filed:
March 28, 2016
Date of Patent:
October 20, 2020
Assignee:
The Translational Genomics Research Institute
Inventors:
Kendall Van Keuren-Jensen, Matthew Huentelman, Ashish Yeri